Successful management of severe refractory acquired immune bleeding disorder: Prior to insisting surgery
Affiliations
Affiliations
- Department of Hematology, Amiri Hospital, Kuwait City, Kuwait. Electronic address: Cbc9@hotmail.com.
- 2Department of Surgery, Amiri Hospital, Kuwait City, Kuwait. Electronic address: Dralbarjas@yahoo.com.
- 3Department of Emergency Medicine and Trauma, Amiri Hospital, Kuwait City, Kuwait. Electronic address: docraed@gmail.com.
- 4Department of Clinical Chemistry, Amiri Hospital, Kuwait City, Kuwait. Electronic address: Kotb.tha@gmail.com.
- 5Department of Pharmacy, Amiri Hospital, Kuwait City, Kuwait. Electronic address: Pharma22@hotmail.com.
Abstract
Introduction: Acquired bleeding disorders are rare and may be missed before surgery. Additionally, they may be refractory to conventional treatments.
Presentation of case: A 50-year-old patient experienced prolonged post-operative bleeding when his bleeding disorder was missed prior to his undergoing inguinal herniorrhaphy. Post-operative investigations revealed severe acquired von Willebrand syndrome associated with a monoclonal gammopathy of undetermined significance. A few months later, he required umbilical herniorrhaphy, but he did not respond to attempts to raise his von Willebrand factor antigen and activity levels using conventional therapies, including desmopressin, cryoprecipitate, intravenous immunoglobulin, and Von Willebrand factor concentrate. A triple therapy combination of dexamethasone, intravenous immunoglobulin, and mycophenolate mofetil was administered, with a successful and sustained response, lasting about 2 months. The surgery was performed safely, without any complications.
Discussion: Conventional acquired von Willebrand syndrome treatment is usually aimed at replacing von Willebrand factor or stimulating its secretion from storage in endothelial cells. In the present case, the alternative treatment was directed against both the humoral and cell-mediated immune mechanisms.
Conclusion: This case of acquired bleeding disorder showed that more attention must be given to a patient's coagulation profile, even if only very minor laboratory coagulation derangements are detected prior to surgery, to avoid missing such rare disorders. The described triple therapy demonstrated good effects and may be considered for inclusion in a controlled randomized study to determine its usefulness for other surgeries delayed due to severe acquired bleeding disorders. To the best of our knowledge, this triple combination treatment has not been previously used for the treatment of severe acquired bleeding disorders that are refractory to conventional therapies.
Keywords: Acquired bleeding disorder; Acquired von Willebrand syndrome; Dexamethasone; Intravenous immunoglobulin; Monoclonal gammopathy; Mycophenolate mofetil; Paraprotein; Surgery.
Similar articles
Lavin M, Brophy TM, Rawley O, O'Sullivan JM, Hayden PJ, Browne PV, Ryan K, O'Connell N, O'Donnell JS.J Thromb Haemost. 2016 Jun;14(6):1200-5. doi: 10.1111/jth.13317. Epub 2016 Apr 27.PMID: 26991062
[Acquired von Willebrand syndrome in three patients and literature review].
Ouyang HY, Yu ZJ, Yin J, Zhao XJ, Wang ZY, Zhang W, Ma ZN, Su J, Bai X, Ruan CG.Zhonghua Xue Ye Xue Za Zhi. 2016 Aug 14;37(8):692-5. doi: 10.3760/cma.j.issn.0253-2727.2016.08.012.PMID: 27587252 Free PMC article. Review. Chinese.
Michiels JJ, Budde U, van der Planken M, van Vliet HH, Schroyens W, Berneman Z.Best Pract Res Clin Haematol. 2001 Jun;14(2):401-36. doi: 10.1053/beha.2001.0141.PMID: 11686107 Review.
[Acquired von Willebrand syndrome: a case series of nine patients and literature review].
Boissier E, Darnige L, Dougados J, Arlet JB, Dupeux S, Georgin-Lavialle S, Caron C, Tapon-Bretaudière J, Pouchot J, Ranque B.Rev Med Interne. 2014 Mar;35(3):154-9. doi: 10.1016/j.revmed.2013.02.039. Epub 2013 Jun 7.PMID: 23746599 Review. French.
Leebeek FWG.Hemasphere. 2021 Jun 1;5(6):e586. doi: 10.1097/HS9.0000000000000586. eCollection 2021 Jun.PMID: 34095769 Free PMC article. Review.
Cited by
Acquired von Willebrand syndrome and lymphoproliferative disorders: A case report.
Nicol C, Raj L, Guillerm G, Couturaud F, Eveillard JR, Pan-Petesch B.Clin Case Rep. 2020 Mar 9;8(5):900-904. doi: 10.1002/ccr3.2770. eCollection 2020 May.PMID: 32477542 Free PMC article.
KMEL References
References
-
- Kumar S., Pruthi R.K., Nichols W.L. Acquired von Willebrand disease. Mayo Clin Proc. 2002;77:181–187. - PubMed
-
- Shetty S., Kasatkar P., Ghosh K. Pathophysiology of acquired von Willebrand disease: a concise review. Eur J Haematol. 2014;87:99–106. - PubMed
-
- Leung L.L.K. ASH Education Book 2006. 2006. Perioperative evaluation of bleeding diathesis; pp. 457–461. - PubMed
-
- Eby C.S. ASH Education Book 2007. 2007. Bleeding and thrombosis risks in plasma cell dyscrasias; pp. 158–164. - PubMed
-
- De Meyer S.F., Deckmyn H., Vanhoorelbeke K. VonWillebrand factor to the rescue. Blood. 2009;113:5049–5057. - PubMed
-
- Tiede A., Rand J.H., Budde U., Ganser A., Federici A.B. How I treat the acquired vonWillebrand syndrome. Blood. 2011;117:6777–6785. - PubMed
-
- Vintimilla M., Joseph A., Ranganathan P. Acquired factor VIII inhibitor in Sjogren's syndrome. Arthritis Care Res (Hoboken) 2010;62:1047–1050. - PubMed
-
- Federici A.B., Rand J.H., Bucciarelli P., Budde U., van Genderen P.J., Mohri H. Subcommittee on von Willebrand Factor: acquired von Willebrand syndrome: data from an international registry. Thromb Haemost. 2000;84:345–349. - PubMed
-
- US National Heart, Lung and Blood Institute . NIH Publication No. 08-5832; Washington, DC: 2007. The diagnosis evaluation and management of Von Willebrand Disease.
-
- Ma A.D., Carrizosa D. Acquired factor VIII inhibitors: pathophysiology and treatment. Hematol Am Soc Hematol Educ Program. 2006:432–437. - PubMed
-
- Franchini M. The use of desmopressin as a hemostatic agent: a concise review. Am J Hematol. 2007;82:731–735. - PubMed
-
- Lindberg L., Forsell C., Jögi P., Olsson A.K. Effects of dexamethasone on clinical course, C-reactive protein, S100B protein and von Willebrand factor antigen after paediatric cardiac surgery. Br J Anaesth. 2003;90:728–732. - PubMed
-
- Crow A.R., Brinc D., Lazarus A.H. New insight into the mechanism of action of IVIg: the role of dendritic cells. J Thromb Haemost. 2009;7(Suppl. 1):245–248. - PubMed
-
- Huraib S.O., Qureshi J.I., Quadri K.H., Al Flaiw A., Al Ghamdi G., Jumani A. Mycophenolate mofetil (MMF) efficacy in glomerulonephritis (GN), a retrospective analysis. Saudi J Kidney Dis Transpl. 2005;16:23–28. - PubMed
-
- Ege H., Besa E.C. Response to treatment with rituximab in a patient with rituximab in a patient with acquired von Willebrand disease. J Oncology. 2002;16(3)
-
- Kumar S., Pruthi R.K., Nichols W.L. Acquired von Willebrand's syndrome: a single institution experience. Am J Hematol. 2003;72:243–247. - PubMed
-
- Gehrs B.C., Friedberg R.C. Autoimmune hemolytic anemia. Am J Hematol. 2002;69:258–271. - PubMed